Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033590912> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3033590912 endingPage "556" @default.
- W3033590912 startingPage "556" @default.
- W3033590912 abstract "556 Purpose: This prospective pilot study investigated the use of 99mTc-HPArk2, an antagonist targeting human epidermal growth factor receptor 2 (HER2), for evaluating breast cancer using SPECT/CT. Methods: With institutional review board approval and informed consent, 20 female patients suspected of breast cancer based on mammography or ultrasonography were recruited. Within 1 week before surgery, the patients underwent SPECT/CT scans at 30 minutes after intravenous injection of approximately 11.1MBq (0.3mCi) per kilogram body weight of 99mTc-HPArk2 and 18F-FDG PET/CT scans 60 minutes after intravenous injection of approximately 5.6MBq (0.15mCi) per kilogram body weight. So far, 15 patients were pathologically diagnosed as breast cancer. Among them, 6 patients had ipsilateral lymph node metastasis. Standardized uptake values (SUV) were obtained by a self-made software and referring to phantom study. Results: No radiopharmaceutical-related adverse event was observed in the patients. 99mTc-HPArk2 SPECT/CT detected the primary tumor well in 14/15 (93%) patients, and the lymph node metastasis in 5/6 (83%) of the patients, whereas the other 1 patient demonstrated only micro-metastasis in lymph nodes. The SUVmax were1.60±0.87 in the breast cancer, and 0.94±0.42 in the lymph node metastasis. The SUVmax of HER2(3+) tumors (2.45±1.19) were significantly higher than those in HER2(-) or HER2(1+) tumors(0.916±0.37, P=0.006).The normal breast tissue (NBT) showed low to moderate 99mTc-HPArk2 binding, with a SUVmax of 0.78±0.31 and a SUVmean of 0.70±0.26. The intensity of 99mTc-HPArk2 uptake in the breast cancer was significantly associated with HER2 immunohistochemistry results. There was a significant positive correlation between the SUVmax of 99mTc-HPArk2 and the HER2 expression level (r = 0.863, P = 0.001). Conclusions: This pilot study indicated that the uptake of HER2 antagonist 99mTc-HPArk2 correlate with HER2 expression in breast cancer. 99mTc-HPArk2 SPECT/CT can provide specific, non-invasive evaluation of HER2 expression in breast cancer." @default.
- W3033590912 created "2020-06-12" @default.
- W3033590912 creator A5041589562 @default.
- W3033590912 creator A5045002695 @default.
- W3033590912 creator A5059704566 @default.
- W3033590912 creator A5071875737 @default.
- W3033590912 creator A5079458179 @default.
- W3033590912 creator A5086183062 @default.
- W3033590912 date "2020-05-01" @default.
- W3033590912 modified "2023-09-26" @default.
- W3033590912 title "99mTc-HPArk2 SPECT/CT in the evaluation of HER2-positive breast cancer: a pilot prospective study" @default.
- W3033590912 hasPublicationYear "2020" @default.
- W3033590912 type Work @default.
- W3033590912 sameAs 3033590912 @default.
- W3033590912 citedByCount "0" @default.
- W3033590912 crossrefType "journal-article" @default.
- W3033590912 hasAuthorship W3033590912A5041589562 @default.
- W3033590912 hasAuthorship W3033590912A5045002695 @default.
- W3033590912 hasAuthorship W3033590912A5059704566 @default.
- W3033590912 hasAuthorship W3033590912A5071875737 @default.
- W3033590912 hasAuthorship W3033590912A5079458179 @default.
- W3033590912 hasAuthorship W3033590912A5086183062 @default.
- W3033590912 hasConcept C121608353 @default.
- W3033590912 hasConcept C126322002 @default.
- W3033590912 hasConcept C126838900 @default.
- W3033590912 hasConcept C142724271 @default.
- W3033590912 hasConcept C188816634 @default.
- W3033590912 hasConcept C2779013556 @default.
- W3033590912 hasConcept C2779720271 @default.
- W3033590912 hasConcept C2780849966 @default.
- W3033590912 hasConcept C2989005 @default.
- W3033590912 hasConcept C530470458 @default.
- W3033590912 hasConcept C71924100 @default.
- W3033590912 hasConceptScore W3033590912C121608353 @default.
- W3033590912 hasConceptScore W3033590912C126322002 @default.
- W3033590912 hasConceptScore W3033590912C126838900 @default.
- W3033590912 hasConceptScore W3033590912C142724271 @default.
- W3033590912 hasConceptScore W3033590912C188816634 @default.
- W3033590912 hasConceptScore W3033590912C2779013556 @default.
- W3033590912 hasConceptScore W3033590912C2779720271 @default.
- W3033590912 hasConceptScore W3033590912C2780849966 @default.
- W3033590912 hasConceptScore W3033590912C2989005 @default.
- W3033590912 hasConceptScore W3033590912C530470458 @default.
- W3033590912 hasConceptScore W3033590912C71924100 @default.
- W3033590912 hasLocation W30335909121 @default.
- W3033590912 hasOpenAccess W3033590912 @default.
- W3033590912 hasPrimaryLocation W30335909121 @default.
- W3033590912 hasRelatedWork W1945787664 @default.
- W3033590912 hasRelatedWork W2013823136 @default.
- W3033590912 hasRelatedWork W2070850268 @default.
- W3033590912 hasRelatedWork W2075721596 @default.
- W3033590912 hasRelatedWork W2314675565 @default.
- W3033590912 hasRelatedWork W2356104290 @default.
- W3033590912 hasRelatedWork W2464552476 @default.
- W3033590912 hasRelatedWork W2604610103 @default.
- W3033590912 hasRelatedWork W2767261848 @default.
- W3033590912 hasRelatedWork W2803603674 @default.
- W3033590912 hasRelatedWork W2883242206 @default.
- W3033590912 hasRelatedWork W2991144455 @default.
- W3033590912 hasRelatedWork W2999100986 @default.
- W3033590912 hasRelatedWork W3009685807 @default.
- W3033590912 hasRelatedWork W3108752302 @default.
- W3033590912 hasRelatedWork W3120757766 @default.
- W3033590912 hasRelatedWork W3121527855 @default.
- W3033590912 hasRelatedWork W3167759437 @default.
- W3033590912 hasRelatedWork W3201082291 @default.
- W3033590912 hasRelatedWork W68070860 @default.
- W3033590912 hasVolume "61" @default.
- W3033590912 isParatext "false" @default.
- W3033590912 isRetracted "false" @default.
- W3033590912 magId "3033590912" @default.
- W3033590912 workType "article" @default.